Skip to content

By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.

Peter Attia MDPeter Attia MD

#21 – Tom Dayspring, M.D., FACP, FNLA – Part II of V: Lipid metrics and cholesterol regulation

Sign up to receive Peter's email newsletter: https://bit.ly/4c602k2 Original release date: 10/16/2018 In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter’s most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part II, Tom provides a 101 on lipids and lipoproteins. Tom and Peter also discuss the history and techniques used to measure lipoproteins, and more. We discuss: -Lipoprotein basics [1:30]; -Gofman and the ultracentrifuge [5:15]; -Lipoprotein structure, function, metabolism [6:45]; -Lipoprotein and cholesterol measurement, and NMR technology [15:15]; -LDL-C vs LDL-P and apoB [30:45]; -Sterols and cholesterol synthesis [39:45]; and -More. Show notes page: https://peterattiamd.com/tomdayspring2/ About: The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 10 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more. Peter is the founder of Attia Medical, PC, a medical practice with offices in San Diego and New York City, focusing on the applied science of longevity. The practice applies nutritional biochemistry, exercise physiology, sleep physiology, techniques to increase distress tolerance, lipidology, pharmacology, and four-system endocrinology to increase lifespan (delaying the onset of chronic disease), while simultaneously improving healthspan (quality of life). Learn more: https://peterattiamd.com/ Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on: Facebook: http://bit.ly/PeterAttiaMDFB Twitter: http://bit.ly/PeterAttiaMDTW Instagram: http://bit.ly/PeterAttiaMDIG Subscribe to The Drive: Apple Podcast: http://bit.ly/TheDriveApplePodcasts Overcast: http://bit.ly/TheDriveOvercast Spotify: http://bit.ly/TheDriveSpotify Google Play: http://bit.ly/TheDriveGooglePlay

Dr. Tom Dayspringguest
Jan 1, 20201h 27mWatch on YouTube ↗

Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.

At a glance

WHAT IT’S REALLY ABOUT

Dayspring Explains Lipoproteins, Cholesterol Metrics, Sterols, and How Cholesterol Is Regulated

  1. Dayspring argues lipids travel through plasma only inside lipoproteins, and atherosclerosis reflects apoB-containing particles delivering sterols to the arterial wall.
  2. The episode traces how lipid measurement evolved from Gofman's ultracentrifuge to total cholesterol, the Friedewald LDL-C calculation, direct assays, and NMR particle counting.
  3. Dayspring says apoB and LDL particle number track risk better than LDL cholesterol, so discordance between them can only be spotted by measuring both.
  4. The speakers cover sterol chemistry and intestinal absorption, describing how NPC1L1, ABCG5/G8, ACAT and ABCA1 let cholesterol in while working to keep phytosterols out.
  5. They discuss cholesterol synthesis and its pathways, the brain's separate cholesterol system, and why plasma cholesterol says little about cellular cholesterol or flux.

IDEAS WORTH REMEMBERING

5 ideas

Lipids need lipoproteins to travel in plasma

Dayspring says plasma is water and lipids are hydrophobic, so they go nowhere unless carried in a lipoprotein; he likens atherosclerosis to illegal dumping of sterols in the artery wall.

ApoB is the one protein that stays on the particle

Other apoproteins can transfer between particles, but apoB stays on chylomicrons, VLDL, IDL and LDL. It acts as the ligand for receptor uptake, and each particle carries one, so apoB serves as a particle count.

Cholesterol metrics are poor-man's proxies for particle number

Dayspring says total cholesterol, LDL-C and non-HDL-C are easily assayed stand-ins, with non-HDL-C correlating with apoB better than LDL-C, which beats total cholesterol.

Discordance means risk follows the particle metric

Dayspring says some people have high apoB or LDL-P with good LDL-C, or the reverse, and in virtually every trial risk follows the particle metric, so both should be measured.

The Friedewald estimate falters as triglycerides rise

It assumes VLDL cholesterol is triglycerides divided by five, but Dayspring says it becomes erroneous somewhere between triglycerides of 150 and 200, and direct LDL-C is better at higher levels.

WORDS WORTH SAVING

5 quotes

if you learn nothing else today, learn the, the first thing is lipids, for the most part, go nowhere in the human body unless they're a passenger inside a lipoprotein.

— Dr. Tom Dayspring

atherosclerosis is just the evidence of illegal dumping, where a lipoprotein, instead of bringing lipids to wherever it's supposed to be bringing it, was bringing sterols to the arterial wall.

— Dr. Tom Dayspring

if you ever go to a doctor and you're told, "I'm very happy 'cause your LDL cholesterol is normal," say, "Well, so am I, doc, but by the way, what was the ApoB or LDL particle count?"

— Dr. Tom Dayspring

It is not possible to discuss lipids without that.

— Dr. Peter Attia

Cholesterol cannot be metabolized and produce ATP in the process.

— Dr. Tom Dayspring

Gofman and lipoprotein densityApoproteins and apoB as structural anchorLDL-C versus LDL-P and apoBFriedewald calculation and direct assaysNMR lipoprotein measurementSterols, stanols and phytosterolsIntestinal absorption and efflux transporters

High quality AI-generated summary created from speaker-labeled transcript.

Get more out of YouTube videos.

Read along on your phone, search it beside the video, or ask your favorite AI app what was said.